US coverage of LVADs (left ventricular assist devices) as destination therapy delayed
This article was originally published in Clinica
The sheer complexity of drafting a coverage decision is reportedly what is holding up Medicare's announcement on whether it intends to cover left ventricular assist devices (LVADs) as destination therapy for beneficiaries with failing hearts who do not qualify for a heart transplant.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.